2-cyclobutyl-1,2-dihydro-4-quinazolinamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-cyclobutyl-1,2-dihydro-4-quinazolinamine
• 英文别名: 2-cyclobutyl-1,2-dihydroquinazolin-4-amine
• 化学式: C₁₂H₁₅N₃
• 分子量: 201.271
• InChiKey: YQSLFNIIJBAELO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氨基苄氨肟 在 镍 氢气 作用下， 以 乙醇 为溶剂， 生成 2-cyclobutyl-1,2-dihydro-4-quinazolinamine
  参考文献：
  名称：

  1,2-Dihydro-4-quinazolinamines:  Potent, Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in Vivo

  摘要：

  The discovery of a novel class of nitric oxide synthase (NOS) inhibitors, 2-substituted 1,2-dihydro-4-quinazo-linamines, and the related 4'-aminospiro[piperidine-4,2'(1'H)-quinazolin]-4'-amines is described. Members of both series exhibit nanomolar potency and high selectivity for the inducible isoform of the enzyme (i-NOS) relative to the constitutive isoforms in vitro. Efficacy in acute and chronic animal models of inflammatory disease following oral administration has also been demonstrated using these compounds.

  DOI：

  10.1021/jm0255926

文献信息

• A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR
  申请人：AstraZeneca AB

  公开号：EP1100505A1

  公开（公告）日：2001-05-23
• US6248745B1
  申请人：——

  公开号：US6248745B1

  公开（公告）日：2001-06-19
• [EN] A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR<br/>[FR] COMPOSITION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE COX-2 ET UN INHIBITEUR DE iNOS
  申请人：ASTRA PHARMA PROD

  公开号：WO2000000200A1

  公开（公告）日：2000-01-06

  The invention relates to the co-administration of an inhibitor of induced nitric oxyde synthase of formula (I) and an inhibitor of cyclooxygenase-2 for the treatment of inflammation and inflammatory disorders.
• 1,2-Dihydro-4-quinazolinamines:  Potent, Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in Vivo
  作者：Alan C. Tinker、Haydn G. Beaton、Nigel Boughton-Smith、Tony R. Cook,、Sally L. Cooper、Lynne Fraser-Rae、Kay Hallam、Peter Hamley、Tom McInally、David J. Nicholls、Austen D. Pimm、Alan V. Wallace

  DOI：10.1021/jm0255926

  日期：2003.3.1

  The discovery of a novel class of nitric oxide synthase (NOS) inhibitors, 2-substituted 1,2-dihydro-4-quinazo-linamines, and the related 4'-aminospiro[piperidine-4,2'(1'H)-quinazolin]-4'-amines is described. Members of both series exhibit nanomolar potency and high selectivity for the inducible isoform of the enzyme (i-NOS) relative to the constitutive isoforms in vitro. Efficacy in acute and chronic animal models of inflammatory disease following oral administration has also been demonstrated using these compounds.